Home・Aktien・Roivant Sciences Ltd

Roivant Sciences Ltd

Geschlossen

BrancheGesundheitswesen

36.15 2.64

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

35.22

Max

36.49

Schlüsselkennzahlen
By Trading Economics
Einkommen	-646M -291M
Verkäufe	-1.1M 1.4M
EPS	-0.45
Gewinnspanne	-20,152.982
Angestellte	721
EBITDA	-743M -288M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+18.19% upside

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	1.8B 26B
Vorheriger Eröffnungskurs	33.51
Vorheriger Schlusskurs	36.15

Roivant Sciences Ltd Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

12. Aug. 2026, 22:11 UTC

Roivant Sciences shares are higher in after-market trading, driven by a positive market reaction to the July Consumer Price Index report.

11. Aug. 2026, 21:01 UTC

Roivant Sciences Ltd shares are lower in after-market hours, continuing recent declines amid broader market volatility linked to U.S.-Iran relations.

10. Aug. 2026, 23:02 UTC

Roivant Sciences Ltd shares are higher in after-market hours, trading above their 20-day moving average and near the upper end of their one-month range.

7. Aug. 2026, 20:02 UTC

Event

News

Roivant Sciences Ltd shares are higher as HC Wainwright maintains a Buy rating and raises the price target to $41 amid positive developments in its product pipeline.

6. Aug. 2026, 20:03 UTC

News

Event

Roivant Sciences reported a net loss of $290.6 million in Q1, exceeding expectations. Shares are higher despite pulling back from session highs earlier.

5. Aug. 2026, 22:01 UTC

Roivant Sciences Ltd shares are higher in after-market trading, reflecting notable activity following Wednesday's close. The stock is positioned above its 20-day moving average.

4. Aug. 2026, 20:02 UTC

Roivant Sciences is rising amid positive market sentiment and declining crude oil prices. Remarks from Treasury Secretary Scott Bessent also support the favorable environment.

3. Aug. 2026, 20:06 UTC

Roivant Sciences Ltd shares are declining today, breaking a trend of higher closes. Broader market indices are up, but no specific news explains the drop.

31. Juli 2026, 20:02 UTC

Roivant Sciences Ltd shares are lower today amid significant declines in biotechnology stocks, breaking a trend of higher daily closes since Thursday.

30. Juli 2026, 23:46 UTC

Roivant Sciences Ltd shares are higher in after-market trading, reflecting a modest gain since Thursday's close. The stock fluctuated within a narrow range.

29. Juli 2026, 23:02 UTC

Roivant Sciences Ltd shares are lower in after-market hours amid broader market concerns and unusual volatility, with no specific company news identified.

28. Juli 2026, 23:06 UTC

Roivant Sciences Ltd shares are lower in after-market hours, continuing a trend of declines over the past three sessions without any specific news to explain the movement.

24. Juli 2026, 18:46 UTC

Roivant Sciences Ltd shares are trading higher, reflecting broader market dynamics amid a rebound in some sectors following a significant decline in oil prices.

23. Juli 2026, 20:06 UTC

Roivant Sciences Ltd is higher during Thursday's session, despite pulling back from an earlier session high. No specific news was identified for the movement.

22. Juli 2026, 22:26 UTC

Roivant Sciences Ltd shares are lower in after-market trading, with no specific news identified to explain the decline amid broader market volatility.

21. Juli 2026, 22:21 UTC

Roivant Sciences Ltd shares are lower in after-market hours, despite a broader market rebound following positive earnings from companies like General Motors and 3M.

20. Juli 2026, 16:36 UTC

Roivant Sciences Ltd. shares are lower today amid ongoing Middle East conflict affecting market sentiment and fluctuations in Brent crude prices.

Peer-Vergleich

Kursveränderung

Roivant Sciences Ltd Prognose

Kursziel

By TipRanks

18.19% Vorteil

12-Monats-Prognose

Durchschnitt 42.29 USD 18.19%

Hoch 50 USD

Tief 37 USD

Basierend auf 7 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Roivant Sciences Ltd – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

7 ratings

Buy

Halten

Sell

Basierend auf 7 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Roivant Sciences Ltd – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.